Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
Weiss Ratings | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Good | |||
Risk Index | Fair | |||
Risk Grade | C- | |||
Reward Grade | B- | |||
Rating Factors | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Excellent | |||
Efficiency Index | Fair | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Fair | |||
Beta / Standard Deviation | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.53 | |||
Price History | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -3.72% | |||
30-Day Total Return | 13.33% | |||
60-Day Total Return | 13.23% | |||
90-Day Total Return | 28.47% | |||
Year to Date Total Return | 12.16% | |||
1-Year Total Return | 19.28% | |||
2-Year Total Return | -0.16% | |||
3-Year Total Return | -9.84% | |||
5-Year Total Return | 25.68% | |||
52-Week High % Change | -7.84% | |||
52-Week Low % Change | 37.74% | |||
Price | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $148.06 | |||
52-Week Low Price | $99.06 | |||
52-Week Low Price (Date) | Jul 10, 2024 | |||
52-Week High Price (Date) | Feb 26, 2025 | |||
Valuation | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 8.29B | |||
Enterprise Value | 11.46B | |||
Price/Earnings (TTM) | 15.53 | |||
Earnings Per Share (TTM) | 8.79 | |||
Earnings Per Share Growth | 43.64% | |||
Price/Earnings To Growth | 0.36 | |||
Price/Sales (TTM) | 2.06 | |||
Price/Book (Q) | 2.02 | |||
Enterprise Value/Revenue (TTM) | 2.82 | |||
Price | $138.81 | |||
Enterprise Value/EBITDA (TTM) | 7.88 | |||
Enterprise Value/EBIT | 14.44 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 61.50M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 353 1 634 7800 | |||
Address | -- | |||
Website | www.jazzpharma.com | |||
Country | Ireland | |||
Year Founded | 2003 | |||
Profitability | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 19.49% | |||
Profit Margin | 13.76% | |||
Management Effectiveness | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 4.24% | |||
Return on Equity | 14.31% | |||
Income Statement | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 4.07B | |||
Total Revenue (TTM) | 4.07B | |||
Revenue Per Share | $66.16 | |||
Gross Profit (TTM) | 3.69B | |||
EBITDA (TTM) | 1.45B | |||
EBIT (TTM) | 793.37M | |||
Net Income (TTM) | 560.12M | |||
Net Income Avl. to Common (TTM) | 560.12M | |||
Total Revenue Growth (Q YOY) | 7.53% | |||
Earnings Growth (Q YOY) | 102.98% | |||
EPS Diluted (TTM) | 8.79 | |||
EPS Diluted Growth (Q YOY) | 118.51% | |||
Balance Sheet | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 2.99B | |||
Cash Per Share (Q) | $48.68 | |||
Total Current Assets (Q) | 4.63B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 4.09B | |||
Current Ratio (Q) | 4.457 | |||
Book Value Per Share (Q) | $67.52 | |||
Total Assets (Q) | 12.01B | |||
Total Current Liabilities (Q) | 1.04B | |||
Total Debt (Q) | 6.17B | |||
Total Liabilities (Q) | 7.92B | |||
Total Common Equity (Q) | 4.09B | |||
Cash Flow | JAZZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -508.20M | |||
Cash from Financing (TTM) | 20.52M | |||
Net Change in Cash (TTM) | 906.55M | |||
Levered Free Cash Flow (TTM) | 1.41B | |||
Cash from Operations (TTM) | 1.40B | |||